Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

56.02 -0.69 (-1.22%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Ionis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
News headline image
Ionis Pharmaceuticals Wins FDA Approval for First Alexander Disease Treatment ↗
Ionis Pharmaceuticals (NASDAQ:IONS) said the U.S. Food and Drug Administration has approved ZANVASTRO as the first and only disease-modifying treatment for Alexander disease, an ultra-rare, progressive... 
Via MarketBeat
News headline image
Here's Why Ionis Pharmaceuticals' Steep Sell-off Was Overdone ↗
This biotech stock looks like a great candidate to buy on the admittedly steep dip. 
Via The Motley Fool
News headline image
Breakfast News: A Conversation With Ionis CEO ↗
Ionis Pharmaceuticals CEO on a major profitability milestone, breakthrough medicines and more. 
Via The Motley Fool
Topics ETFs World Trade
Ionis Pharmaceuticals (NASDAQ:IONS) Surges After Q2 Earnings Beat Estimates ↗
Via Chartmill
Topics Earnings
Ionis Pharmaceuticals (NASDAQ:IONS) Shares Surge After Crushing Q1 Estimates and Raising Full-Year Guidance ↗
Via Chartmill
News headline image
Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing ↗
Yes, Alnylam has had some bad news. But the bad news isn't as horrible as many think. 
Via The Motley Fool
News headline image
Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock? ↗
A drug that didn't meet expectations in a trial is to blame. 
Via The Motley Fool
News headline image
Ionis (IONS) Q2 2026 Earnings Call Transcript ↗
Revenue hit $268 million with 56% growth, while TRYNGOLZA sales accelerated. 
Via The Motley Fool
Topics Earnings
Ionis Pharmaceuticals (NASDAQ:IONS) Shows High Technical and Setup Ratings for Potential Breakout ↗
Via Chartmill
News headline image
Ionis Pharmaceuticals Director Hayden Buys $1.1 Million Shares. What Does This Mean for Investors? ↗
Insider holdings surged 34% through indirect acquisition, signaling confidence amid company's $8.8 billion valuation and RNA-therapy pipeline advancement. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Ionis Pharmaceuticals Q2 Earnings Call Highlights ↗
Ionis Pharmaceuticals (NASDAQ:IONS) reported second-quarter revenue growth driven by commercial products and partnered research programs, while highlighting the recent U.S. approval and early launch... 
Via MarketBeat
Topics Earnings
News headline image
Cathie Wood Just Bet Big on This Biotech Stock ↗
Ionis Pharmaceuticals' shares are down more than 27% so far this year. What does Cathie Wood see that others are missing? 
Via The Motley Fool
Topics ETFs
News headline image
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions ↗
Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals. 
Via MarketBeat
Which stocks are experiencing notable movement on Thursday? ↗
Via Chartmill
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
Discover the top movers in Thursday's pre-market session. ↗
Via Chartmill
News headline image
QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now ↗
Mornings like we had on Wednesday are exactly why I get up and do this show every single day the market is open. UniQure NV (QURE) opened around $43. Touched $48.88 intraday. Closed in the high $47s.... 
Via InvestorPlace
News headline image
This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter ↗
This clinical-stage biotech develops precision genetic medicines for neurological and hepatic disorders via its PRISM platform. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Ionis Pharmaceuticals Eyes Big Year With TRYNGOLZA Decision, 5 Phase 3 Readouts ↗
Ionis Pharmaceuticals (NASDAQ:IONS) highlighted a busy slate of regulatory decisions, clinical readouts and partnered programs during a presentation at RBC Capital Markets’ Global Healthcare... 
Via MarketBeat
News headline image
Ionis Pharmaceuticals Touts $3B TRYNGOLZA Opportunity, Pipeline Readouts at Conference ↗
Executives at a healthcare investor event outlined commercial launch plans, pipeline readouts and market-development priorities across several biotechnology franchises, with discussion spanning Ionis... 
Via MarketBeat
News headline image
Ionis (IONS) Q1 2026 Earnings Call Transcript ↗
Ionis (IONS) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Ionis (IONS) Q4 2025 Earnings Transcript ↗
Ionis (IONS) Q4 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Wave Life Sciences Shakes Biotech Sector with Breakthrough Obesity Data: A New Era for ‘Quality’ Weight Loss
The biotechnology landscape witnessed a defining moment on March 26, 2026, as Wave Life Sciences (Nasdaq: WVE) released highly anticipated interim Phase 1 data from its INLIGHT trial. The study, which... 
Via MarketMinute
News headline image
When Insider Selling Is a Good Thing: 2 Stocks to Watch ↗
Ionis Pharmaceuticals and Waste Management insiders sell in early 2026, creating buying opportunities in their stocks while analysts raise price targets. 
Via MarketBeat
News headline image
Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026 ↗
This clinical-stage biotech develops precision therapies for genetically defined diseases, targeting rare cancers and systemic mastocytosis. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position ↗
This biotech firm develops targeted oncology therapies and leverages proprietary technology to address tumor resistance mechanisms. 
Via The Motley Fool
News headline image
Hedge Fund Boone Capital Initiated a Stake in HealthEquity. Is the Stock a Buy? ↗
HealthEquity delivers cloud-based healthcare savings solutions to employers and individuals, with a broad client network across the U.S. 
Via The Motley Fool
News headline image
Vertex Pharmaceuticals Surges 8.3% as Renal Breakthrough Sparks Market Rally
In a significant milestone for precision medicine, Vertex Pharmaceuticals (NASDAQ:VRTX) emerged as the top performer in the S&P 500 on March 11, 2026, with its shares climbing 8.3%. The rally followed... 
Via MarketMinute
Topics Stocks
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.